Endocannabinoid-Boosting Drug Shows Neuroprotective Promise in HIV Brain Disease Model

In vitro, ABX1431 completely reversed Tat-induced neuronal calcium overexcitement at all tested concentrations, partially through CB1 receptors. In vivo, ABX1431 increased locomotor activity and significantly upregulated 2-AG levels in the striatum and spinal cord. CB2 receptor levels increased in treated control mice but not HIV-model mice.

Combined in vitro (frontal cortex neuronal calcium imaging) and in vivo (HIV-1 Tat transgenic mouse model) approach. ABX1431 tested at 10, 30, 100 nM in vitro and 4 mg/kg in vivo. Assessed antinociception (tail-flick, hot plate), locomotion, endocannabinoid levels (mass spectrometry), and receptor expression (western blot).

HIV-associated neurological disease affects up to 50% of people living with HIV despite antiretroviral therapy. Boosting the brain's own endocannabinoid system -- rather than using external cannabinoids -- represents a more targeted approach that could avoid the psychoactive effects of THC while still activating protective cannabinoid pathways.

MAGL inhibitors represent a fundamentally different strategy from exogenous cannabinoids. Instead of flooding cannabinoid receptors with plant-derived compounds, they amplify the body's own endocannabinoid signaling at sites where it's already active, potentially providing more targeted and physiologically appropriate neuroprotection.

The Tat transgenic mouse model represents only one aspect of HIV neuropathology. Acute treatment results may not reflect chronic use outcomes. The differential CB2R response between Tat+ and Tat- mice complicates interpretation. Human translation requires clinical trials.